Bacteremia is a life-threating syndrome often caused by methicillin-resistant Staphylococcus aureus (MRSA). Thus, there is an urgent need to develop novel approaches to successfully treat this
infection. Staphylococcal accessory regulator A (SarA), a global virulence regulator, plays a critical role in pathogenesis and β-
lactam antibiotic resistance in Staphylococcus aureus.
Hypericin is believed to act as an
antibiotic,
antidepressant,
antiviral and non-specific
kinase inhibitor. In the current study, we investigated the impact of
hypericin on β-
lactam antibiotics susceptibility and mechanism(s) of its activity. We demonstrated that
hypericin significantly decreased the minimum inhibitory concentrations of β-
lactam antibiotics (e.g.,
oxacillin,
cefazolin and
nafcillin), biofilm formation and
fibronectin binding in MRSA strain JE2. In addition,
hypericin significantly reduced sarA expression, and subsequently decreased
mecA, and virulence-related regulators (e.g., agr RNAⅢ) and genes (e.g., fnbA and hla) expression in the studied MRSA strain. Importantly, the in vitro synergistic effect of
hypericin with β-
lactam antibiotic (e.g.,
oxacillin) translated into in vivo therapeutic outcome in a murine MRSA
bacteremia model. These findings suggest that
hypericin plays an important role in abrogation of β-
lactam resistance against MRSA through sarA inhibition, and may allow us to repurpose the use of β-
lactam antibiotics, which are normally ineffective in the treatment of MRSA
infections (e.g.,
oxacillin).